Skip to main content

Table 2 Cox proportional regression analysis for progression-free survival and overall survival

From: High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR

Variable

PFS

OS

Univariate

Multivariate

Univariate

HR

p

HR

p

HR

p

(95% CI)

(95% CI)

(95% CI)

Age

 0.96

0.657

  

 1.11

0.374

(<57 vs. γ 57)

(0.79 to 1.16)

(0.88 to 1.41)

Gender

 0.63

< 0.001

0.87

0.310

 0.54

< 0.001

(female vs. male)

(0.52 to 0.77)

(0.66 to 1.14)

(0.42 to 0.69)

Smoking status

 1.57

< 0.001

1.25

0.102

 1.67

< 0.001

(never vs. ever)

(1.29 to 1.92)

(0.96 to 1.64)

(1.31 to 2.12)

Histology

 1.37

0.009

0.94

0.673

 1.25

0.133

(ADC vs. non-ADC)

(1.08 to 1.75)

(0.72 to 1.24)

(0.93 to 1.68)

Stage

 1.00

0.976

  

 0.87

0.190

(IIIb vs. IV)

(0.83 to 1.20)

(0.70 to 1.07)

ECOG

 2.45

< 0.001

2.53

< 0.001

 4.43

< 0.001

(0, 1 vs. 2, 3)

(1.95 to 3.08)

(1.97 to 3.24)

(3.33 to 5.89)

LINE

 1.32

0.006

1.06

0.618

 1.40

0.006

(first-line vs. γ second-line)

(1.09 to 1.61)

(0.85 to 1.32)

(1.10 to 1.78)

EGFR-TKI

 1.14

0.201

  

 1.14

0.312

(gefitinib vs. erlotinib)

(0.93 to 1.40)

(0.89 to 1.46)

EGFR mutation

 0.37

< 0.001

0.42

<0.001

 0.45

< 0.001

(wild-type vs. mutation)

(0.31 to 0.45)

(0.34 to 0.53)

(0.36 to 0.58)

EGFR FISH

 0.51

< 0.001

0.61

<0.001

 0.51

< 0.001

(FISH- vs. FISH+)

(0.42 to 0.62)

(0.49 to 0.76)

(0.40 to 0.65)

  1. Abbreviation: ADC, Adenocarcinoma; ECOG, Eastern cooperative oncology group; TKI, Tyrosine kinase inhibitors; FISH, Fluorescent in situ hybridization.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us